News | November 15, 2025
Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities
The observations are procedural in nature and will be responded to within the stipulated time
The observations are procedural in nature and will be responded to within the stipulated time
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Fenebrutinib targets cells in the immune system known as B cells and microglia
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Subscribe To Our Newsletter & Stay Updated
